What is Orphazyme?
Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, Inclusion Body Myositis, and Gaucher disease. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark. Orphazyme establishes a U.S.
What are analysts'price targets for Orphazyme a/s's share price?
2 equities research analysts have issued 1 year price targets for Orphazyme A/S's stock. Their forecasts range from $5.00 to $27.00. On average, they anticipate Orphazyme A/S's share price to reach $16.00 in the next twelve months. This suggests a possible upside of 186.7% from the stock's current price.
What is the company registration number for Orphazyme?
Orphazyme A/SCompany announcementNo. 27/2021Company Registration No. 32266355 Copenhagen – December 9, 2021 – Orphazyme A/S (ORPHA.CO; ORPH or the “Company”), a late-stage biopharmaceutical company, today announces changes to the Board of Directors, following Catherine Moukheibir’s decision to step down from her position as of December 9, 2021.
Will Orphazyme as sponsored ADR (Orph) gain on rising earnings prospects?
Orphazyme AS Sponsored ADR (ORPH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Should I sell Orphazyme stock?
Is Orphazyme A/S stock A Buy? Orphazyme A/S holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.
Is Orph getting delisted?
Orphazyme (NASDAQ:ORPH) is falling after the drugmaker announced today that it would delist its American Depositary Shares. The company said that it had started the delisting process and noted that it will take effect on March 31.
Is ORPH stock a buy right now?
2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Orphazyme A/S in the last twelve months. There are currently 1 se...
Who are Orphazyme A/S's key executives?
Orphazyme A/S's management team includes the following people: Mr. Anders Fink Vadsholt M.B.A. , M.Sc., MBA, Chief Financial Officer (Age 52, Pa...
Who are some of Orphazyme A/S's key competitors?
Some companies that are related to Orphazyme A/S include Eliem Therapeutics (ELYM) , Immunic (IMUX) , Checkpoint Therapeutics (CKPT) , Adagene...
When did Orphazyme A/S IPO?
(ORPH) raised $100 million in an IPO on Tuesday, September 29th 2020. The company issued 7,600,000 shares at $13.13 per share. BofA Securities, Cow...
What is Orphazyme A/S's stock symbol?
Orphazyme A/S trades on the NASDAQ under the ticker symbol "ORPH."
Who are Orphazyme A/S's major shareholders?
Orphazyme A/S's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Simplex Trading LLC (0.00%...
Which institutional investors are selling Orphazyme A/S stock?
ORPH stock was sold by a variety of institutional investors in the last quarter, including HAP Trading LLC, Cutler Group LP, and Group One Trading...
Which institutional investors are buying Orphazyme A/S stock?
ORPH stock was acquired by a variety of institutional investors in the last quarter, including Simplex Trading LLC.
How much money does Orphazyme A/S make?
Orphazyme A/S (NASDAQ:ORPH) has a market capitalization of $0.00.